Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the University Health Network Research Ethics Board ("UHN REB") has granted ethics approval for St. Michael's H
(Financial Post, 2025-12-16T12:42:34Z)